Resum
Idioma original | Anglès |
---|---|
Revista | BMC Medicine |
Volum | 14 |
Número | 1 |
DOIs | |
Estat de la publicació | Publicada - 2016 |
SDG de les Nacions Unides
Aquest resultat contribueix als següents objectius de desenvolupament sostenible.
Accés al document
Fingerprint
Navegar pels temes de recerca de 'Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration'. Junts formen un fingerprint únic.Com citar-ho
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: BMC Medicine, Vol. 14, Núm. 1, 2016.
Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts
TY - JOUR
T1 - Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration
AU - Sabin, C.A.
AU - Reiss, P.
AU - Ryom, L.
AU - Phillips, A.N.
AU - Weber, R.
AU - Law, M.
AU - Fontas, E.
AU - Mocroft, A.
AU - de Wit, S.
AU - Smith, C.
AU - Dabis, F.
AU - d'Arminio Monforte, A.
AU - El-Sadr, W.
AU - Lundgren, J.D.
AU - Powderly, B.
AU - Shortman, N.
AU - Moecklinghoff, C.
AU - Reilly, G.
AU - Franquet, X.
AU - Kamara, D.
AU - Phillips, C.
AU - Bojesen, A.
AU - Nielsen, J.
AU - Raben, D.
AU - Salbøl Brandt, R.
AU - Rickenbach, M.
AU - Fanti, I.
AU - Krum, E.
AU - Hillebregt, M.
AU - Geffard, S.
AU - Sundström, A.
AU - Delforge, M.
AU - Torres, F.
AU - McManus, H.
AU - Wright, S.
AU - Kjær, S.
AU - Sjøl, A.
AU - Meidahl, P.
AU - Helweg-Larsen, J.
AU - Schmidt Iversen, J.
AU - Group, for the D:A:D Study
N1 - Cited By :79 Export Date: 17 February 2022 Correspondence Address: Sabin, C.A.; University College London (UCL), Royal Free Campus, United Kingdom; email: [email protected] Chemicals/CAS: abacavir, 136470-78-5, 188062-50-2; abacavir; Anti-HIV Agents; Dideoxynucleosides Funding details: CT94-1637, CT97-2713 Funding details: FIS 99/0887 Funding details: FIPSE 3171/00 Funding details: National Institutes of Health, NIH Funding details: U.S. Food and Drug Administration, FDA Funding details: National Institute of Allergy and Infectious Diseases, NIAID, U01AI042170, U01AI046362, U01AI069907 Funding details: Bristol-Myers Squibb, BMS Funding details: Pfizer Funding details: GlaxoSmithKline, GSK Funding details: Merck Funding details: Roche Funding details: Gilead Sciences Funding details: AbbVie Funding details: F. Hoffmann-La Roche Funding details: Boehringer Ingelheim Funding details: Janssen Pharmaceuticals, CURE/97-46486 Funding details: European Commission, EC Funding details: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, SNF Funding details: University of New South Wales, UNSW Funding details: Agence Nationale de Recherches sur le Sida et les Hépatites Virales, ANRS Funding details: Department of Health, Australian Government Funding details: Fifth Framework Programme, FP5, QLK2-2000-00773 Funding details: European Medicines Agency, EMA Funding text 1: This work was supported by the Highly Active Antiretroviral Therapy Oversight Committee (HAART-OC), a collaborative committee with representation from academic institutions, the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA), the patient community, and all pharmaceutical companies with licensed anti-HIV drugs in the European Union: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F. Hoffman-La Roche and Janssen Pharmaceuticals. Supported by a grant [grant number CURE/97-46486] from the Health Insurance Funds Council, Amstelveen, The Netherlands, to the AIDS Therapy Evaluation in the Netherlands (ATHENA) project; by a grant from the Agence Nationale de Recherches sur le sida [grant number Action Coordonnée no.7, Cohortes], to the Aquitaine Cohort; The Australian HIV Observational Database (AHOD) is funded as part of the Asia Pacific HIV Observational Database, a program of The American Foundation for AIDS Research, amfAR, and is supported in part by a grant from the United States National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) [grant number U01-AI069907], and by unconditional grants from Merck, Gilead Sciences, Bristol-Myers Squibb, Boehringer Ingelheim, Roche, Pfizer, GlaxoSmithKline and Janssen Pharmaceuticals. The Kirby Institute is funded by The Australian Government Department of Health, and is affiliated with the Faculty of Medicine, The University of New South Wales (UNSW). By grants from the Fondo de Investigación Sanitaria [grant number FIS 99/0887] and Fundación para la Investigación y la Prevención del Sida en Espanã [grant number FIPSE 3171/00], to the Barcelona Antiretroviral Surveillance Study (BASS); by the National Institute of Allergy and Infectious Diseases, National Institutes of Health [grant numbers 5U01AI042170-10, 5U01AI046362-03], to the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); by grants from the BIOMED 1 [grant number CT94-1637] and BIOMED 2 [grant number CT97-2713] programs and the fifth framework program [grant number QLK2-2000-00773] of the European Commission, and grants from Bristol-Myers Squibb, GlaxoSmithKline, Boehringer Ingelheim and Roche, to the EuroSIDA study; by unrestricted educational grants of AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer and Janssen Pharmaceuticals to the Italian Cohort Naive to Antiretrovirals (The ICONA Foundation); and by a grant from the Swiss National Science Foundation, to the Swiss HIV Cohort Study (SHCS). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above. Funding text 2: LR, JDL, WES, SdW, FD and EF have no conflicts of interest. PR has served as a scientific advisor to Bristol-Myers Squibb, Gilead Sciences, Grupo Ferrer, GlaxoSmithKline, Janssen Pharmaceuticals, Merck and ViiV Healthcare. He has served on data and safety monitoring boards and endpoint adjudication committees for Janssen Pharmaceuticals, and his institution has received honoraria for speaking engagements at scientific conferences from Bristol-Myers Squibb, Gilead Sciences and GlaxoSmithKline. He has received research support from Gilead Sciences, ViiV Healthcare, Merck, Janssen Pharmaceuticals, Bristol-Myers Squibb, Abbott and Boehringer Ingelheim. ML has received research grants from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Merck, Pfizer and F. Hoffman-La Roche. AM has received consultancy fees, honoraria and speaker fees from Bristol-Myers Squibb, Pfizer, Merck, Boehringer Ingelheim and Gilead Sciences. Ad’M has past board membership at AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals and Merck. CS has a pending grant from Bristol-Myers Squibb, and received payment for development of educational presentations by Gilead Sciences, ViiV Healthcare and Janssen Pharmaceuticals. ANP received personal fees from Gilead Sciences, AbbVie, GlaxoSmithKline Vaccines and grants from Bristol-Myers Squibb. CAS has served on data and safety monitoring boards for ViiV Healthcare and Janssen-Cilag, and has received honoraria for the development of educational materials and membership of speaker panels from Gilead Sciences, Janssen-Cilag, ViiV Healthcare and Bristol-Myers Squibb. References: Sabin, C., Worm, S., Weber, R., El-Sadr, W., Reiss, P., Thiebaut, R., Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? (2008) Poster 957c. 15th Conference on Retroviruses and Opportunistic Infections, , Boston, 3-6 February; Sabin, C.A., Worm, S.W., Weber, R., Reiss, P., El-Sadr, W., Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration (2008) Lancet, 371, pp. 1417-1426; Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients (2008) AIDS, 22, pp. F17-24; Martin, A., Bloch, M., Amin, J., Baker, D., Cooper, D.A., Emery, S., Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96 week trial (2009) Clin Infect Dis, 49, pp. 1591-1601; Obel, N., Farkas, D.K., Kronborg, G., Larsen, C.S., Pedersen, G., Riis, A., Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study (2010) HIV Med, 11, pp. 130-136; Durand, M., Sheehy, O., Baril, J.G., Lelorier, J., Tremblay, C.L., Association between HIV infection, antiretroviral therapy, and risk of myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database (2011) J Acquir Immune Defic Syndr, 57, pp. 245-253; Choi, A.I., Vittinghoff, E., Deeks, S.G., Weekley, C.C., Li, Y., Shlipak, M.G., Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons (2011) AIDS, 25, pp. 1289-1298; Palella, F.J., Althoff, K.N., Moore, R., Zhang, J., Kitahata, M., Gange, S.J., Abacavir use and risk for myocardial infarction in the NA-ACCORD. Poster 749LB (2015) 22nd Conference on Retroviruses and Opportunistic Infections, , Seattle, 23-26 February; Young, J., Xiao, Y., Moodie, E.E.M., Abrahamowicz, M., Klein, M.B., Bernasconi, E., Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study (2015) J Acquir Immune Defic Syndr, 69, pp. 413-421; Triant, V.A., Regan, S., Lee, H., Sax, P.E., Meigs, J.B., Grinspoon, S.K., Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system (2010) J Acquir Immune Defic Syndr, 55, pp. 615-619; Brothers, C.H., Hernandez, J.E., Cutrell, A.G., Curtis, L., Ait-Khaled, M., Bowlin, S.J., Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects (2009) J Acquir Immun Defic Syndr, 51, pp. 20-28; Ribaudo, H.J., Benson, C.A., Zheng, Y., Koletar, S.L., Collier, A.C., Lok, J.J., No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT (2011) Clin Infect Dis, 52, pp. 929-940; Lang, S., Mary-Krause, M., Cotte, L., Gilquin, J., Partisani, M., Simon, A., Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients (2010) Arch Int Med, 170, pp. 1228-1238; Bedimo, R.J., Westfall, A.O., Brechsler, H., Vidiella, G., Tebas, P., Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era (2011) Clin Infect Dis, 53, pp. 84-91; Ding, X., Andraca-Carrera, E., Cooper, C., Miele, P., Kornegay, C., Soukup, M., No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis (2012) J Aquir Immun Defic Syndr, 61, pp. 441-447; Cruciani, M., Zanichelli, V., Serpelloni, G., Bosco, O., Malena, M., Mazzi, R., Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data (2011) AIDS, 25, pp. 1993-2004; Satchell, C.S., O'Halloran, J.A., Cotter, A.G., Peace, A.J., O'Connor, E.F., Tedesco, A.F., Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy (2011) J Infect Dis, 204, pp. 1202-1210; Baum, P.D., Sullam, P.M., Stoddart, C.A., McCune, J.M., Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase (2011) AIDS, 25, pp. 2243-2248; Falcinelli, E., Francisci, D., Belfiori, B., Petito, E., Guglielmini, G., Malincarne, L., In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients (2013) Thromb Haemost, 110, pp. 349-357; Katlama, C., Fenske, S., Gazzard, B., Lazzarin, A., Clumeck, N., Mallolas, J., TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results (2003) HIV Med, 4, pp. 79-86; Sabin, C.A., Worm, S., Phillips, A.N., Lundgren, J.D., Abacavir and increased risk of myocardial infarction. Authors' reply (2008) Lancet, 372, pp. 804-805; British HIV Association Guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2014) HIV Med, 15, pp. 1-85; (2013), www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf, Version 7.0. Accessed 14 Oct 2014; Antoniou, T., Gillis, J., Loutfy, M.R., Cooper, C., Hogg, R.S., Klein, M.B., Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naïve, HIV-infected patients in Canada (2014) J Int Assoc Prov AIDS Care, 13, pp. 153-159; Friis-Møller, N., Reiss, P., Sabin, C.A., Weber, R., Monforte, A.D., Class of antiretroviral drugs and the risk of myocardial infarction (2007) N Engl J Med, 356, pp. 1723-1735; Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.M., Pamak, A., Myocardial infarction and coronary deaths in the World Health Organization MONICA Project registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents (1994) Circulation, 90, pp. 583-612; Friis-Moller, N., Thiebaut, R., Reiss, P., Weber, R., Monforte, A.D., Wit, S., Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study (2010) Eur J Cardiovasc Prev Rehabil, 17, pp. 491-501; Mallon, P.W., Impact of nucleoside reverse transcriptase inhibitors on coronary heart disease (2014) Rev Cardiovasc Med, 15, pp. S21-S29; Bavinger, C., Bendavid, E., Niehaus, K., Olshen, R.A., Olkin, I., Sundaram, V., Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review (2013) PLoS One, 8; Desai, M., Joyce, V., Bendavid, E., Olshen, R.A., Hlatky, M., Chow, A., Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US Veteran population (2015) Clin Infect Dis, 61, pp. 445-452; Marcus, J.L., Neugebauer, R.S., Leyden, W.A., Chao, C.R., Xu, L., Quesenberry, C.P., Use of abacavir and risk of cardiovascular disease among HIV-infected individuals (2016) J Acquir Immune Defic Syndr, 71 (4), pp. 413-419; Brouwer, E.S., Napravnik, S., Eron, J.J., Stalzer, B., Floris-Moore, M., Simpson, R.J., Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients (2014) Epidemiology, 25, pp. 406-417; Martin, A., Amin, J., Cooper, D.A., Carr, A., Kelleher, A.D., Bloch, M., Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial (2010) AIDS, 24, pp. 2657-2663; Ford, E.S., Grenwald, J.H., Richterman, A.G., Rupert, A., Dutcher, L., Badralmaa, Y., Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection (2010) AIDS, 24, pp. 1509-1517; Kaplan, R.C., Landay, A.L., Hodis, H.N., Gange, S.J., Norris, P.J., Young, M., Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment (2012) J Acquir Immun Defic Syndr, 60, pp. 359-368; McComsey, G.A., Kitch, D., Daar, E.S., Tierney, C., Jahed, N.C., Melbourne, K., Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir (2012) AIDS, 26, pp. 1371-1385; Rasmussen, T.A., Tolstrup, M., Melchjorsen, J., Frederiksen, C.A., Nielsen, U.S., Langdahl, B.L., Evaluation of cardiovascular biomarkers in HIV-infected persons switching to abacavir or tenofovir based therapy (2011) BMC Infect Dis, 11, p. 267; Hileman, C.O., Wohl, D.A., Tisch, D.J., Debanne, S.M., McComsey, G.A., Initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens (2012) AIDS Res Hum Retrovir, 28, pp. 1561-1564; Hsue, P.Y., Hunt, P.W., Wu, Y., Schnell, A., Jo, J.E., Hatano, H., Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients (2009) AIDS, 23, pp. 2021-2027; McComsey, G.A., Kitch, D., Sax, P.E., Tierney, C., Jahed, N.C., Melbourne, K., Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202 (2014) J Acquir Immune Defic Syndr, 65, pp. 167-174; Hammond, E., McKinnon, E., Mallal, S., Nolan, D., Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy (2008) AIDS, 22, pp. 2540-2543; Wohl, D.A., Arnoczy, G., Fichtenbaum, C.J., Campbell, T., Taiwo, B., Hicks, C., Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study (2014) Antiviral Ther, 19, pp. 141-147; Patel, P., Bush, T., Overton, T., Baker, J., Hammer, J., Kojic, E., Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction (2012) Antiviral Ther, 17, pp. 755-761; Martinez, E., Larrousse, M., Podzamczer, D., Perez, I., Gutierrez, F., Lonca, M., Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction (2010) AIDS, 24, pp. F1-F9; Luca, A., de Gaetano Donati, K., Cozzi-Lepri, A., Colafigli, M., Curtis, A., Capobianchi, M.R., Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study (2012) J Acquir Immun Defic Syndr, 60, pp. e98-e100; Pablo, C., Orden, S., Apostolova, N., Blanquer, A., Esplugues, J.V., Alvarez, A., Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation (2010) AIDS, 24, pp. 1259-1266; Pablo, C., Orden, S., Peris, J.E., Barrachina, M.D., Esplugues, J.V., Alvarez, A., Profile of leukocyte-endothelial cell interactions induced in venules and arterioles by nucleoside reverse-transcriptase inhibitors in vivo (2013) J Infect Dis, 208, pp. 1448-1453; Pablo, C., Orden, S., Calatayud, S., Marti-Cabrera, M., Esplugues, J.V., Alvarez, A., Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment (2012) Antivir Ther, 17, pp. 1615-1619; Papakonstantinou, V.D., Chini, M., Mangafas, N., Stamatakis, G.M., Tsogas, N., Tsoupras, A.B., In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients (2014) Lipids Health Dis, 13, p. 90; Piconi, S., Parisotto, S., Rizzardini, G., Passerini, S., Meraviglia, P., Schiavini, M., Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals (2013) AIDS, 27, pp. 381-389; Chini, M., Tsoupras, A.B., Mangafas, N., Tsogas, N., Papakonstantinou, V.D., Fragopoulou, E., Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naïve HIV-infected patients: ii) study of the abacavir/lamivudine/Efavirenz HAART regimen (2012) Int J Immunopathol Pharmacol, 25, pp. 247-258; Haugaard, A.K., Lund, T.T., Birch, C., Fonsholt, F., Troseid, M., Ullum, H., Discrepant coagulation profile in HIV infection: elevated D-dimer but impaired platelet aggregation and clot initiation (2013) AIDS, 27, pp. 2749-2758; Danaei, G., Tavakkoli, M., Hernán, M.A., Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins (2012) Am J Epidemiol, 175, pp. 250-262
PY - 2016
Y1 - 2016
N2 - Background: In March 2008, the D:A:D study published results demonstrating an increased risk of myocardial infarction (MI) for patients on abacavir (ABC). We describe changes to the use of ABC since this date, and investigate changes to the association between ABC and MI with subsequent follow-up. Methods: A total of 49,717 D:A:D participants were followed from study entry until the first of an MI, death, 1 February 2013 or 6 months after last visit. Associations between a person's 10-year cardiovascular disease (CVD) risk and the likelihood of initiating or discontinuing ABC were assessed using multivariable logistic/Poisson regression. Poisson regression was used to assess the association between current ABC use and MI risk, adjusting for potential confounders, and a test of interaction was performed to assess whether the association had changed in the post-March 2008 period. Results: Use of ABC increased from 10 % of the cohort in 2000 to 20 % in 2008, before stabilising at 18-19 %. Increases in use pre-March 2008, and subsequent decreases, were greatest in those at moderate and high CVD risk. Post-March 2008, those on ABC at moderate/high CVD risk were more likely to discontinue ABC than those at low/unknown CVD risk, regardless of viral load (≤1,000 copies/ml: relative rate 1.49 [95 % confidence interval 1.34-1.65]; >1,000 copies/ml: 1.23 [1.02-1.48]); no such associations were seen pre-March 2008. There was some evidence that antiretroviral therapy (ART)-naïve persons at moderate/high CVD risk post-March 2008 were less likely to initiate ABC than those at low/unknown CVD risk (odds ratio 0.74 [0.48-1.13]). By 1 February 2013, 941 MI events had occurred in 367,559 person-years. Current ABC use was associated with a 98 % increase in MI rate (RR 1.98 [1.72-2.29]) with no difference in the pre- (1.97 [1.68-2.33]) or post- (1.97 [1.43-2.72]) March 2008 periods (interaction P = 0.74). Conclusions: Despite a reduction in the channelling of ABC for patients at higher CVD risk since 2008, we continue to observe an association between ABC use and MI risk. Whilst confounding cannot be fully ruled out, this further diminishes channelling bias as an explanation for our findings. © 2016 Sabin et al.
AB - Background: In March 2008, the D:A:D study published results demonstrating an increased risk of myocardial infarction (MI) for patients on abacavir (ABC). We describe changes to the use of ABC since this date, and investigate changes to the association between ABC and MI with subsequent follow-up. Methods: A total of 49,717 D:A:D participants were followed from study entry until the first of an MI, death, 1 February 2013 or 6 months after last visit. Associations between a person's 10-year cardiovascular disease (CVD) risk and the likelihood of initiating or discontinuing ABC were assessed using multivariable logistic/Poisson regression. Poisson regression was used to assess the association between current ABC use and MI risk, adjusting for potential confounders, and a test of interaction was performed to assess whether the association had changed in the post-March 2008 period. Results: Use of ABC increased from 10 % of the cohort in 2000 to 20 % in 2008, before stabilising at 18-19 %. Increases in use pre-March 2008, and subsequent decreases, were greatest in those at moderate and high CVD risk. Post-March 2008, those on ABC at moderate/high CVD risk were more likely to discontinue ABC than those at low/unknown CVD risk, regardless of viral load (≤1,000 copies/ml: relative rate 1.49 [95 % confidence interval 1.34-1.65]; >1,000 copies/ml: 1.23 [1.02-1.48]); no such associations were seen pre-March 2008. There was some evidence that antiretroviral therapy (ART)-naïve persons at moderate/high CVD risk post-March 2008 were less likely to initiate ABC than those at low/unknown CVD risk (odds ratio 0.74 [0.48-1.13]). By 1 February 2013, 941 MI events had occurred in 367,559 person-years. Current ABC use was associated with a 98 % increase in MI rate (RR 1.98 [1.72-2.29]) with no difference in the pre- (1.97 [1.68-2.33]) or post- (1.97 [1.43-2.72]) March 2008 periods (interaction P = 0.74). Conclusions: Despite a reduction in the channelling of ABC for patients at higher CVD risk since 2008, we continue to observe an association between ABC use and MI risk. Whilst confounding cannot be fully ruled out, this further diminishes channelling bias as an explanation for our findings. © 2016 Sabin et al.
KW - Abacavir
KW - Cardiovascular disease
KW - Channelling bias
KW - Confounding
KW - Myocardial infarction
KW - Risk
KW - abacavir
KW - 2',3' dideoxynucleoside derivative
KW - anti human immunodeficiency virus agent
KW - adult
KW - Article
KW - cardiovascular risk
KW - cohort analysis
KW - disease association
KW - drug effect
KW - drug use
KW - female
KW - heart infarction
KW - high risk patient
KW - human
KW - Human immunodeficiency virus infection
KW - major clinical study
KW - male
KW - risk assessment
KW - virus load
KW - Australia
KW - clinical practice
KW - drug surveillance program
KW - Europe
KW - HIV Infections
KW - medication therapy management
KW - middle aged
KW - Myocardial Infarction
KW - odds ratio
KW - procedures
KW - risk factor
KW - statistical model
KW - statistics and numerical data
KW - trends
KW - United States
KW - Adult
KW - Anti-HIV Agents
KW - Dideoxynucleosides
KW - Female
KW - Humans
KW - Logistic Models
KW - Male
KW - Medication Therapy Management
KW - Middle Aged
KW - Odds Ratio
KW - Pharmacovigilance
KW - Practice Patterns, Physicians'
KW - Risk Assessment
KW - Risk Factors
U2 - 10.1186/s12916-016-0588-4
DO - 10.1186/s12916-016-0588-4
M3 - Article
C2 - 27036962
SN - 1741-7015
VL - 14
JO - BMC Medicine
JF - BMC Medicine
IS - 1
ER -